IFNA1 and systemic lupus erythematosus: Administration of IFNα was shown to enhance thrombosis and platelet activation in a lupus-prone mouse model (78) and high IFNα levels have been suggested as an independent risk factor for cardiovascular disease in both SLE and RA (69, 80).